Why could patients with heart failure and T2DM benefit from SGLT2 inhibition?
Topic:
Pathophysiology and Mechanisms
Speaker:
Professor S. Verma (Toronto, CA)
Organised by PACE-CME, Physicians' Academy for Cardiovascular Education, supported with an educational grant from Boehringer Ingelheim
Event:
Heart Failure 2019
Congress Presentation
About the speaker
Professor Subodh Verma
St. Michael's Hospital, Toronto (Canada)
27
presentations
0
follower
4 more presentations in this session
Real world practices and outcomes in the management of heart failure patients with T2DM.
Speaker: Professor C. Lam (Singapore, SG)
The future of SGLT2 inhibition in heart failure: managing patients without T2DM?
Speaker: Professor A. Voors (Groningen, NL)
Panel discussion - Heart Failure, diabetes & SGLT2 inhibition: time to change practice?
Speaker: Professor M. Cowie (Cambridge, GB)
Access the full session
Heart Failure, diabetes & SGLT2 inhibition: time to change practice?
Speakers:
Professor S. Verma, Professor M. Cowie, Professor C. Lam, Professor A. Voors, Professor M. Cowie
About the event
ESC 365 is supported by
